Company Overview

Acutus Medical, Inc. is a U.S.-based medical technology company focused on the diagnosis and treatment of complex cardiac arrhythmias, particularly atrial fibrillation (AF) and ventricular arrhythmias. The company operates within the cardiac electrophysiology segment of the broader medical devices industry, developing technologies intended to improve the precision and efficiency of arrhythmia mapping and ablation procedures. Its core value proposition centers on enabling electrophysiologists to visualize and treat arrhythmias with greater accuracy compared to conventional mapping approaches.

The company’s primary revenue drivers have historically included advanced cardiac mapping systems, diagnostic catheters, and related accessories used in hospital electrophysiology labs. Acutus differentiates itself through high-resolution, noncontact mapping technology designed to rapidly map complex arrhythmias. Acutus Medical was founded in 2011 by Randall Wolf, a cardiothoracic surgeon and electrophysiologist, and went public in 2020. Since its IPO, the company has undergone multiple strategic and financial restructurings as it sought to scale adoption of its technology amid competitive and reimbursement pressures in the electrophysiology market.

Business Operations

Acutus Medical’s operations have centered on the development, manufacturing, and commercialization of its electrophysiology mapping and ablation platform, most notably the Acutus AcQMap® System and associated diagnostic and ablation catheters. Revenue has primarily been generated through direct sales of capital equipment, disposable catheters, and service contracts, largely to hospitals and specialized cardiac centers. The company has operated with a combination of direct sales personnel and distributor relationships, depending on geography.

Operations have included both domestic and international commercialization, with regulatory clearances obtained in the United States, Europe, and select other markets. Acutus controls proprietary mapping software, catheter designs, and related intellectual property. Over time, the company streamlined its portfolio and divested certain non-core assets; details of some later-stage operational changes and asset dispositions remain data inconclusive based on available public sources, particularly following financial restructuring actions disclosed in recent SEC filings.

Strategic Position & Investments

Strategically, Acutus Medical has aimed to position itself as a next-generation electrophysiology platform provider capable of addressing unmet needs in complex arrhythmia treatment. Growth initiatives have historically focused on expanding clinical evidence, increasing physician adoption, and broadening indications for its mapping technology. The company has also pursued cost-reduction initiatives and balance-sheet stabilization in response to sustained operating losses and liquidity constraints.

Acutus has engaged in selective divestitures and restructuring transactions to concentrate on its core electrophysiology technologies. Certain asset sales and strategic transactions with larger industry participants have been disclosed in SEC filings, though public information regarding the long-term impact of these actions on competitive positioning is limited. The company has not historically maintained a broad portfolio of unrelated subsidiaries, instead operating primarily through its core operating entity and wholly owned subsidiaries supporting international sales.

Geographic Footprint

Acutus Medical is headquartered in Carlsbad, California, and has historically maintained its primary research, development, and administrative operations in the United States. The company has also supported commercial activities across Europe and parts of the Asia-Pacific region through a combination of direct operations and distribution partners.

International presence has been oriented around markets with established electrophysiology procedure volumes, including key countries in Western Europe. While Acutus has reported revenue contributions from outside the United States, the U.S. market has remained its most significant source of sales. The scale and scope of international operations have fluctuated over time in line with strategic realignments and cost-control efforts.

Leadership & Governance

Acutus Medical was founded by Randall Wolf – Founder, whose clinical background in electrophysiology influenced the company’s technology-driven approach. The leadership team has emphasized physician-centric innovation, clinical data generation, and disciplined capital allocation, particularly following the company’s post-IPO financial challenges.

Key executives reported in recent public disclosures include:

• David Roman – President and Chief Executive Officer
• Randall Wolf – Founder and Chief Medical Officer
• Keith A. Hurlbut – Chief Financial Officer
• Christopher A. Rowland – Chief Commercial Officer

Leadership composition and roles have evolved over time, and certain executive changes disclosed in SEC filings reflect the company’s restructuring efforts. Where more recent confirmations are unavailable, data inconclusive based on available public sources.